文献速递头颈外科

第二胸椎骨性标志用于头颈癌患者骨骼肌评估及CT定义肌少症评价

The use of the second thoracic vertebral landmark for skeletal muscle assessment and computed tomography-defined sarcopenia evaluation in patients with head and neck cancer.
PubMed 文献 · Head Neck · 2023-02-21

本研究利用诊断性PET-CT扫描,在111例头颈癌患者中建立以第二胸椎骨骼肌横截面积预测第三腰椎横截面积的模型,并评估该模型及肿瘤特异性生存。预测公式相关性良好(r=0.796,ICC=0.882,p<0.001),敏感度82.8%、特异度78.2%,一致性中等(ƙ=0.540,p<0.001);T2-SMI较低四分位组5年肿瘤特异性生存较差(51%,p=0.003)。结论认为T2骨骼肌可有效用于头颈癌CT定义肌少症评估。

要点

  • 预测公式:L3-CSA(cm²)=174.15+[0.212×T2-CSA(cm²)]-[40.032×性别]-[0.928×年龄(岁)]+[0.285×体重(kg)]。
  • 模型相关性r=0.796、ICC=0.882(p<0.001),敏感度82.8%、特异度78.2%,一致性中等(ƙ=0.540,p<0.001)。
  • T2-SMI较低四分位组5年肿瘤特异性生存为51%(p=0.003)。

核心结论

  • T2水平骨骼肌可有效用于头颈癌患者CT定义肌少症评估。

研究设计与样本

  • 利用诊断性PET-CT扫描开发以T2-CSA预测L3-CSA的模型,并评估模型有效性及肿瘤特异性生存,共评估111例患者(85%男性)。

主要发现

  • 预测公式为L3-CSA(cm²)=174.15+[0.212×T2-CSA(cm²)]-[40.032×性别]-[0.928×年龄(岁)]+[0.285×体重(kg)],相关性r=0.796、ICC=0.882(p<0.001)。
  • 骨骼肌指数(SMI)平均差值(偏倚)为-3.6%(SD 10.2,95%CI -8.7%至1.3%)。
  • 敏感度82.8%、特异度78.2%,一致性中等(ƙ=0.540,p<0.001)。
  • T2-SMI较低四分位组5年肿瘤特异性生存为51%(p=0.003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The cross-sectional area (CSA) of skeletal muscle (SM) at the third lumbar vertebra (L3) is used to determine computed tomography (CT)-defined sarcopenia. We investigated the feasibility of SM assessment at the second thoracic vertebra (T2) in patients with head and neck cancer (HNC). METHODS: Diagnostic PET-CT scans were used to develop a prediction model for L3-CSA using T2-CSA. Effectiveness of the model and cancer-specific survival (CSS) were investigated. RESULTS: Scans of 111 patients (85% male) were evaluated. The predictive formula: L3-CSA (cm2 ) = 174.15 + [0.212 × T2-CSA (cm2 )] - [40.032 × sex] - [0.928 × age (years)] + [0.285 × weight (kg)] had good correlation r = 0.796, ICC = 0.882 (p < 0.001). SM index (SMI) mean difference (bias) was -3.6% (SD 10.2, 95% CI -8.7% to 1.3%). Sensitivity (82.8%), specificity (78.2%), with moderate agreement (ƙ = 0.540, p < 0.001). Worse 5-year CSS with lower quartile T2-SMI (51%, p = 0.003). CONCLUSIONS: SM at T2 can be effectively used for CT-defined sarcopenia evaluation in HNC.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Vangelov B, Bauer J, Moses D, et al. The use of the second thoracic vertebral landmark for skeletal muscle assessment and computed tomography-defined sarcopenia evaluation in patients with head and neck cancer. Head Neck. 2023. PMID: 36811256. doi:10.1002/hed.27320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。